Vitae Pharma Reports Positive Phase 2a Results For Psoriasis Treatment VTP …

Vitae Pharma Reports Positive Phase 2a Results For Psoriasis Treatment VTP …

“While the autoimmune market is currently dominated by injectable antibody therapy, we believe VTP-43742 has the potential to expand utilization of oral therapy in a variety of autoimmune disorders, such as psoriasis, psoriatic arthritis, rheumatoid

(Visited 1 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.